Last reviewed · How we verify
NCT07042841
AI-Driven Quantitative Decision and Surgical Planning System for Liver Cancer
trial in Liver Cancer, Adult in 300 participants. Enrolling by invitation.
30 December 2024
Quick facts
| Lead sponsor | Beijing Tsinghua Chang Gung Hospital |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 30 June 2015 |
| Primary completion | 30 December 2024 |
| Estimated completion | 30 October 2027 |
| Sites | 1 location across China |
Conditions studied
- Liver Cancer, Adult — all drugs for Liver Cancer, Adult →
Sponsor
Beijing Tsinghua Chang Gung Hospital
Who can join
18 and older, any sex, with Liver Cancer, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to develop and validate an integrated AI-powered system for liver cancer that includes intelligent tumor boundary detection, micro-metastasis prediction, staging, treatment decision-making, and surgical planning. The system builds upon prior 3D reconstructions of liver, vessels, and bile ducts. In a retrospective multi-center, self-controlled, fully crossed multi-reader multi-case clinical trial, the researchers will compare diagnostic accuracy, staging, and planning performance between AI-assisted reads and conventional reads using CT images and pathological gold standards.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07042841
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Cancer, Adult
Currently open trials in the same condition.
- NCT07295262 — NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC · EARLY_PHASE1 · recruiting
- NCT07315633 — An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies fo · recruiting
- NCT07345247 — RAdiation SEgmentectomy With REsin Microspheres (RASEREM) Study · recruiting
- NCT06689540 — Mts105 for Advanced Hepatocellular Carcinoma · Phase 1 · recruiting
- NCT07070362 — Digital Early Warning System for Acute Lung Injury in Liver Surgery · recruiting
Other Beijing Tsinghua Chang Gung Hospital trials
Trials by the same sponsor.
- NCT07123675 — AI-Assisted Blood Pressure Control During Anesthesia · NA · not yet recruiting
- NCT07152496 — Host-Microbe Interactions in Biliary Dilatation · not yet recruiting
- NCT07330271 — PTC-Guided Therapy for Peritoneal Mesothelioma · NA · recruiting
- NCT07328737 — One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei · NA · recruiting
- NCT07044947 — Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC） · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07042841 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tsinghua Chang Gung Hospital
- Last refreshed: 29 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07042841.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing